Source-grounded facts extracted from Dianthus Therapeutics, Inc. /DE/'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Dianthus Therapeutics, Inc. /DE/ received a nasdaq deficiency notice notice regarding minimum bid price (rules 5810(c)(3)(A)).
“January 31, 2023, Magenta Therapeutics, Inc. (the “Company”) received a written notice from the staff (the “Staff”) of the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”), notifying the Company that, for the 30 consecutive business day period between December 15, 2022 through January 30, 2023, the Company’s common stock, $0.001 par value per share (the “Common Stock”), had not maintained a minimum bid price of $1.00 per share, required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The”
Earnings Releases
Dianthus Therapeutics, Inc. /DE/ reported financial results for third quarter ending September 30, 2022.
“Magenta Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2022. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.”
Michael Vasconcelles was appointed as Director at Dianthus Therapeutics, Inc. /DE/.
“On August 15, 2022, the Board of Directors (the “Board”) of Magenta Therapeutics, Inc. (the “Company”) unanimously appointed Michael Vasconcelles to the Board.”
Alison F. Lawton was appointed as Chair of the Board at Dianthus Therapeutics, Inc. /DE/.
“Alison F. Lawton, currently a member of the Board, was appointed Chair of the Board”
Michael W. Bonney resigned as Director at Dianthus Therapeutics, Inc. /DE/.
“On August 3, 2021, Michael W. Bonney notified the Company of his intent to resign from the Company’s Board of Directors (the “Board”) and its committees effective August 3, 2021, to focus on his newly expanded role as Executive Chair of Alnylam Pharmaceuticals, Inc.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.